Literature DB >> 12067934

Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes.

P G Steg1, B Iung, L J Feldman, D Cokkinos, J Deckers, K A A Fox, U Keil, A P Maggioni.   

Abstract

BACKGROUND: It has been suggested that patients undergoing acute intervention for coronary syndromes may not receive adequate secondary prevention.
OBJECTIVE: To analyse the impact of availability and use of coronary interventions on the prescription of secondary prevention after acute coronary syndromes.
DESIGN: Analysis of a prospective multicentre register of patients admitted to hospital for acute coronary syndromes.
SETTING: A 1999 pan-European survey in 390 hospitals. PATIENTS: 3092 patients admitted to hospital with acute coronary syndromes (including 777 for ST elevation myocardial infarction within 12 hours of onset). MAIN OUTCOME MEASURES: Rates of prescription of aspirin and lipid lowering agents.
RESULTS: Performance of coronary angiography and percutaneous coronary interventions (PCI) during the hospital stay were independent predictors of prescription of aspirin at discharge (odds ratio (OR) 1.29 and 1.89, p = 0.053 and p < 0.0001, respectively). Lipid lowering agents were prescribed more often on discharge in patients admitted to hospitals with catheterisation laboratories than without (for infarction with ST elevation, 45% v 40% (NS); for other acute coronary syndromes, 46% v 36%; p < 0.05). Prescription rates were higher among patients undergoing coronary angiography or PCI than in those treated conservatively (for infarction with ST elevation, 49%, 53%, and 39%, p < 0.05; for other acute coronary syndromes, 50%, 54%, and 34%, p < 0.05). Logistic regression analysis showed that PCI was an independent predictor of prescription of lipid lowering agents at discharge (OR 1.48, p < 0.0002).
CONCLUSIONS: Contrary to expectations, invasive procedures for acute coronary syndromes are associated with higher rates of prescription of pharmacological secondary prevention.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12067934      PMCID: PMC1767154          DOI: 10.1136/heart.88.1.20

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  20 in total

1.  The heart in context.

Authors: 
Journal:  Lancet       Date:  2000-09-09       Impact factor: 79.321

2.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Authors:  G G Schwartz; A G Olsson; M D Ezekowitz; P Ganz; M F Oliver; D Waters; A Zeiher; B R Chaitman; S Leslie; T Stern
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

3.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

4.  Early statin treatment following acute myocardial infarction and 1-year survival.

Authors:  U Stenestrand; L Wallentin
Journal:  JAMA       Date:  2001 Jan 24-31       Impact factor: 56.272

5.  Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events.

Authors: 
Journal:  Lancet       Date:  2001-03-31       Impact factor: 79.321

6.  Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme.

Authors: 
Journal:  Eur Heart J       Date:  2001-04       Impact factor: 29.983

7.  Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3.

Authors:  G C Fonarow; W J French; L S Parsons; H Sun; J A Malmgren
Journal:  Circulation       Date:  2001-01-02       Impact factor: 29.690

8.  Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study.

Authors:  A M Tonkin; D Colquhoun; J Emberson; W Hague; A Keech; G Lane; S MacMahon; J Shaw; R J Simes; P L Thompson; H D White; D Hunt
Journal:  Lancet       Date:  2000-12-02       Impact factor: 79.321

9.  The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment.

Authors:  K A Fox; D V Cokkinos; J Deckers; U Keil; A Maggioni; G Steg
Journal:  Eur Heart J       Date:  2000-09       Impact factor: 29.983

10.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.

Authors:  T A Pearson; I Laurora; H Chu; S Kafonek
Journal:  Arch Intern Med       Date:  2000-02-28
View more
  5 in total

1.  The use of lipid-lowering therapy for secondary prevention in patients undergoing percutaneous coronary intervention.

Authors:  Jessica M Ma; Cynthia A Jackevicius; Uchenwa Genus; Vladimir Dzavik
Journal:  Can J Cardiol       Date:  2006-04       Impact factor: 5.223

2.  Patients with acute coronary syndrome should start a statin while still in hospital.

Authors:  C G Isles
Journal:  Heart       Date:  2002-07       Impact factor: 5.994

3.  A clearly visible V wave in the pulmonary artery pressure curve caused by severe mitral valve regurgitation.

Authors:  K de Man; G S de Ruiter; P A van der Wouw
Journal:  Neth Heart J       Date:  2006-09       Impact factor: 2.380

4.  How equitable are GP practice prescribing rates for statins?: an ecological study in four primary care trusts in North West England.

Authors:  Paul R Ward; Peter R Noyce; Antony S St Leger
Journal:  Int J Equity Health       Date:  2007-03-27

5.  Exploring the equity of GP practice prescribing rates for selected coronary heart disease drugs: a multiple regression analysis with proxies of healthcare need.

Authors:  Paul R Ward; Peter R Noyce; Antony S St Leger
Journal:  Int J Equity Health       Date:  2005-02-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.